Loading...
01/11 16:19
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several concerning factors: a significant decline in revenue, a reduced cash position, and geopolitical risks. Despite some positive developments like the acquisition of Lavie Bio and reduced expenses, the dependency on collaborations and the absence of license fee payments pose substantial risks. Additionally, the financial sustainability is questionable due to decreased cash reserves and reliance on future funding. The analysts' sentiment is unclear, but the overall financial picture and risks suggest a negative market reaction.
Total Revenues $2.4 million (decrease of approximately 43% year-over-year from $4.2 million); decline primarily due to $3.5 million in license fee payments recognized in Q1 2024 from collaborations with Corteva and Bayer.
R&D Expenses $3.2 million (decrease of approximately 33% year-over-year from $4.8 million); decrease mainly due to reduced R&D activity in Biomica and Lavie Bio.
Sales and Marketing Expenses $0.6 million (decrease of approximately 35% year-over-year from $1 million); decrease primarily due to reduced sales and marketing activities in Lavie Bio.
Total Operating Expenses $5 million (decrease of approximately 38% year-over-year from $8 million); decrease mainly due to reduced operating activity in Lavie Bio and Biomica.
Cash and Short-term Deposits $9.8 million (decrease from $15.3 million as of December 31, 2024); cash balance does not reflect approximately $2 million due from Casterra's outstanding customers.
Net Loss $3 million (decrease of approximately 21% year-over-year from $3.8 million); decrease primarily due to reduced operating expenses and increased net financing income.
Net Financing Income $1.1 million (compared to net financing income of approximately $241,000 in the same period last year); increase primarily due to accounting treatment of pre-funded warrants and warrants issued in August 2024.
ChemPass-AI for Pharma: Substantial advancement in refining ChemPass-AI's value proposition for pharmaceutical and biotech sectors, focusing on designing novel compounds.
BMC128: Phase I clinical study of BMC128 shows early signs of effectiveness through immune activation within 14 days.
AgPlenus Fungicide Discovery: Discovery of a new mode of action for fungicides against Septoria in wheat, with plans to engage licensing partners by year-end.
Casterra Seed Sales: Casterra delivered 250 tons of castor seeds to partners in Africa, surpassing 2024's total of 215 tons.
Lavie Bio Acquisition by ICL: ICL to acquire Lavie Bio's activities for $15.25 million and Evogene's MicroBoost AI tech-engine for $3.5 million.
Expense Reduction Plan: Evogene established an expense reduction plan expected to be completed by Q2 2025, reflected in reduced R&D and operating expenses.
Cash Position: As of Q1 2025, Evogene's cash and short-term deposits were approximately $9.8 million, excluding $2 million due from Casterra's customers.
Focus on AI-driven Drug Discovery: Evogene aims to position itself as a leader in AI-driven drug discovery, integrating life science expertise with advanced computational technologies.
Exit Strategy for Subsidiaries: Evogene is focusing on creating exit events for subsidiaries to generate value and cash for the company and its shareholders.
Geopolitical Risks: The ongoing war between Israel, Hamas, and Hezbollah poses significant risks to Evogene's operations, particularly if the situation escalates further.
Regulatory Risks: The acquisition of Lavie Bio by ICL is subject to customary and regulatory closing conditions, including approvals from antitrust authorities and the Israeli Innovation Center.
Financial Risks: Evogene's cash balance has decreased from approximately $15.3 million to $9.8 million, raising concerns about financial sustainability. The company is also dependent on additional funding for Biomica to advance to Phase II of its clinical study.
Revenue Risks: Total revenues for Q1 2025 were approximately $2.4 million, a significant decrease from $4.2 million in Q1 2024, primarily due to the absence of license fee payments that were present in the previous year.
Operational Risks: The company has implemented an expense reduction plan, which indicates potential operational challenges and the need for cost management.
Market Demand Risks: While there is growing interest in castor oil, the company faces challenges in educating farmers on how to cultivate castor effectively, which could impact future sales.
Dependency on Collaborations: Evogene's revenue generation is heavily reliant on collaborations and partnerships, which may pose risks if these partnerships do not yield expected results.
Expense Reduction Plan: Evogene established an expense reduction plan, which will be completed by the second quarter of 2025, already partially reflected in Q1 2025 results.
Acquisition of Lavie Bio by ICL: Evogene announced the acquisition of most of Lavie Bio's activity by ICL for an aggregate value of $15.25 million, expected to close in Q2 2025.
ChemPass-AI Development: Evogene is focusing on enhancing its ChemPass-AI tech-engine for drug discovery, aiming to position itself as a leader in the pharmaceutical sector.
Casterra Seed Sales: Casterra has delivered 250 tons of castor seeds in Q1 2025, with expectations for additional orders and trials in Brazil and Kenya.
AgPlenus Fungicide Discovery: AgPlenus announced a new mode of action for fungicides against Septoria in wheat, with plans to engage licensing partners by year-end.
Biomica Clinical Study: Biomica's Phase I clinical study of BMC128 is progressing, with early signs of effectiveness and a need for additional funding to advance to Phase II.
Revenue Expectations: Total revenues for Q1 2025 were approximately $2.4 million, a decrease from $4.2 million in Q1 2024, primarily due to the absence of prior license fee payments.
Cash Position: As of March 31, 2025, Evogene held approximately $9.8 million in cash and short-term deposits, excluding $2 million due from Casterra's customers.
Financial Outlook: Evogene expects to maintain a strong financial position until the end of 2026, assuming conservative revenue projections and continued expense management.
Acquisition Value from ICL: Evogene announced the acquisition of most of Lavie Bio's activity by ICL for an aggregate value of $15.25 million.
MicroBoost AI Sale: ICL will acquire Evogene's MicroBoost AI tech-engine for agriculture for approximately $3.5 million.
Expected Cash Inflow: Evogene expects to receive $3.5 million directly from the sale of MicroBoost AI and additional funds from Lavie Bio's operations post-acquisition.
Future Revenue from Collaborations: Evogene anticipates future revenue from existing collaboration agreements with Syngenta and Corteva.
The earnings call reveals a mixed but overall positive sentiment. Financial performance shows improvement in net loss and operating loss, though revenues slightly decreased. The AI ChemPass platform is gaining interest, with potential partnerships on the horizon. Management's enthusiasm for AI ChemPass and planned IR activities could boost investor confidence. Despite some unclear responses in the Q&A, the focus on strategic partnerships and financial health supports a positive outlook for stock price movement.
The earnings call highlights strong revenue growth, significant reductions in operating expenses, and promising developments in castor seed sales and field trials. The Q&A section reveals optimism about future collaborations and advancements, particularly in the ChemPass AI platform. Despite some vague responses, the focus on new strategies and partnerships suggests a positive outlook. The financial improvements and strategic plans indicate a likely stock price increase of 2% to 8% over the next two weeks.
The earnings call presents a mixed picture. While there are positive developments, such as the acquisition of Lavie Bio by ICL and reduced expenses, there are concerns over declining revenues, operational risks, and funding challenges. The Q&A session highlights management's reluctance to provide clear guidance, raising uncertainties. Despite reduced expenses and a cash inflow from asset sales, the reliance on subsidiaries for revenue and the lack of clarity on future orders temper optimism. Given these factors, the stock price is likely to remain stable, resulting in a neutral sentiment.
The earnings call reveals several concerning factors: a significant decline in revenue, a reduced cash position, and geopolitical risks. Despite some positive developments like the acquisition of Lavie Bio and reduced expenses, the dependency on collaborations and the absence of license fee payments pose substantial risks. Additionally, the financial sustainability is questionable due to decreased cash reserves and reliance on future funding. The analysts' sentiment is unclear, but the overall financial picture and risks suggest a negative market reaction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
